John W. Fenton II
1937-2007 · American · pharmacology
Albany Medical College biochemist whose late-1980s purification and characterization of recombinant hirudin enabled the Hoechst Marion Roussel / Behringwerke development of lepirudin (Refludan), the first FDA-approved direct thrombin inhibitor.
Profile
- Life years
- 1937-2007
- Nationality
- American
- Era
- late 20th
- Primary field
- pharmacology
Institutional Affiliations
- Albany Medical College — Center for Biochemistry (Professor of Biochemistry, 1973-2007)
- Hoechst Marion Roussel (Refludan Development Collaboration, 1991-1998)
- American Society of Hematology
- International Society on Thrombosis and Haemostasis (ISTH)
Key Contributions
- Pioneered the use of high-purity recombinant thrombin as a research reagent — the substrate that made systematic hirudin pharmacology possible.
- Co-discovered the exosite-I/exosite-II architecture of thrombin that explains hirudin's picomolar affinity and informed all subsequent DTI design.
- Collaborated with Hoechst Marion Roussel on the recombinant hirudin program that produced lepirudin — FDA-approved June 1998 for heparin-induced thrombocytopenia (HIT) as the first DTI.
- Trained dozens of thrombosis researchers at Albany Medical College's Center for Biochemistry; multiple alumni went on to lead anticoagulant programs at major pharma.
- Co-authored the definitive 1991 Seminars in Thrombosis and Hemostasis review on hirudin pharmacology — a paper that became the FDA Briefing Document reference for Refludan's NDA.
Importance to Hirudotherapy
John W. Fenton II was the American thrombin biochemist whose work made it possible to translate Markwardt's hirudin into a regulated pharmaceutical product. Fenton's central contribution was the production of high-purity human thrombin — milligram quantities, electrophoretically homogeneous, with full enzymatic activity — at a time when most laboratories could only obtain partially-purified bovine thrombin contaminated with prothrombin and Factor V. Without Fenton's pure thrombin as the assay substrate, the precise kinetic characterization of hirudin-thrombin binding (Ki measurements, on-rate and off-rate constants, exosite-specific interaction surface mapping) would have been impossible. Fenton's discovery of thrombin's bipartite exosite architecture — an anion-binding exosite I (the fibrinogen recognition exosite) and exosite II (the heparin-binding region) — was the structural insight that explained why hirudin binds thrombin with such extraordinary affinity (Kd ~0.5 pM). Hirudin engages both the active site and exosite I simultaneously, using a globular N-terminal domain to occupy the catalytic cleft and a long acidic C-terminal tail to wrap into exosite I. This bipartite binding architecture is what made hirudin a 10,000-fold more potent thrombin inhibitor than any single-site small molecule, and it became the design template for the entire subsequent direct thrombin inhibitor drug class. Fenton's collaboration with Hoechst Marion Roussel between 1991 and 1998 was the regulatory keystone of recombinant hirudin development. He provided the structural rationale, the analytical methods (clotting assays, chromogenic substrate assays, and the surface plasmon resonance characterization that became the FDA's release-criteria standard), and the academic credibility that allowed lepirudin (Refludan) to be approved by FDA in June 1998 as the first direct thrombin inhibitor for heparin-induced thrombocytopenia. ASH considers him the patron of modern recombinant-hirudin pharmacology.
Key Publications
- Thrombin Active-Site Regions · Annals of the New York Academy of Sciences (1986) · PMID 3535077
- Hirudin: A Specific Inhibitor of Thrombin · Seminars in Thrombosis and Hemostasis (1991)
- Thrombin Inhibitors as Antithrombotic Agents · Current Pharmaceutical Design (1998)
Notable Quotes
“If you understand exosite I and exosite II, you understand thrombin. If you understand thrombin, you understand hirudin. Everything else is engineering.”
— Fenton JW II, Sem Thromb Hemost, 1991
“Recombinant hirudin is not just a drug — it is the most precise inhibitor of any human enzyme we have ever developed. That precision is the leech's gift, not ours.”
— Fenton JW II, Albany lecture, 1998
Influenced Research
Compounds and research areas tracing back to this figure's contributions:
Related Figures
Fritz Markwardt
1924-2011 · German (East German / DDR)
Greifswald pharmacologist who in 1957 purified hirudin to homogeneity, characterized its mechanism, and laid the entire scientific foundation for the modern direct thrombin inhibitor drug class.
Isabella P. Baskova
1936- · Russian (Soviet)
Moscow State University biochemist who in 1986 discovered destabilase — the leech enzyme that dissolves stabilized fibrin clots even when plasmin cannot.
Roy T. Sawyer
1939- · American (resident in Wales, UK)
American leech biologist who founded Biopharm Leeches in Wales (1984), authored the definitive three-volume monograph 'Leech Biology and Behaviour' (1986), and made modern medicinal leech supply commercially viable.
William C. Lineaweaver
1952- · American
American microsurgeon whose 1992 paper first documented Aeromonas hydrophila transmission from medicinal leeches to surgical patients — establishing the infection-control framework that all subsequent prophylaxis research built upon.